CSPC Pharmaceutical Group (HKG:1093) presented data from a phase I clinical study of SYS6002 as a rapid oral presentation at the 2026 Annual Global Meeting of the International Gynecologic Cancer Society.

The trial testing the drug as monotherapy for the treatment of advanced cervical cancer found it to have a manageable safety profile and preliminary efficacy, a Thursday bourse filing showed.

The drug is currently being studied for the treatment of advanced cervical cancer previously treated with immunotherapy in a phase III trial.